CytoMed gets Nasdaq minimum bid deficiency notice
CytoMed Therapeutics said Nasdaq notified it that its ordinary shares closed below the minimum bid price for 30 consecutive business days. The company has until April 5, 2027, to regain compliance.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.